BioLatam Digital 2024

8–12 abr 2024

Elvira Zini

Scientific & Technical Affairs Director

Laboratorios Richmond SACIF

Buenos Aires, Argentina

21 visitas al perfilPonentePonente

In charge of biotech & small chemical entities R&D, Regulatory Activities, Licensees and Tech Transfer agreements.


Elvira Zini, M.Sc. is the Scientific & Technical Affairs Director of Laboratorios Richmond SACIF Argentina, a LATAM Pharmaceutical and Biotech company where she has been working since 1996 and in charge of different positions. She has vast experience in the pharmaceutical industry, she also worked 10 years for Boehringer Ingelheim, R&D Division and  for John Wyeth.

She has a Master Degree in Chemical Sciences, Biological Chemistry Orientation, College of Exact and Natural Sciences-UBA Argentina, and received many post graduate education.; i.e. Pharmaceutical Technology Training at Pharmacy College Ghent University Belgium, that acceded through a Scholarship of the Foreign Trade and Development Cooperation Ministry, Kingdom of Belgium. She also has business education, i.e. PDD IAE Business School, Universidad Austral, Argentina

She is one of the founders of a NGO, “De La Nada Asociación Civil”, where she is a volunteer for more than 23 years.

Mi organización

Laboratorios Richmond SACIF

Regional pharmaceutical company based in Argentina devoted to the development and manufacture of technologically advanced pharmaceutical products.

Richmond believes that health-care is not a privilege. This right implies providing equality of access to the best treatments, also to therapies which would make access difficult due to their high costs.
the product portfolio  includes biosimilar products, vaccines, generic products  licenses and technology transfers from central countries. In addition, we have developed innovative solutions which combine different active ingredients in a single tablet presented in user friendly packaging for ease of transportation and intake. This allows patients to adhere to the treatment while enjoying an active life.

During 2024 a new state-of-art vaccines & biotechnology facility is being opened, facility that includes premium technology for drug substance and drug product manufacturing. Supportive comprehensive quality control labs and pilot plant for process development and technology transfer.


  • R&D
  • Drug Regulatory Affairs


  • Business oportunites
  • CDMO service provider
  • vaccines
  • Biosimilars

Preguntas adicionales

¿Cuáles son sus áreas de negocio?

CRO/CMOBiotecnología salud humanaIndustria farmacéutica

What are your intends at this event?

Find a Project PartnerBuy new productsSell their productsExpand their network

Sesiones de ponente (1)

lunes, 8 de abril de 2024

16:50 - 17:35

Convergencia regulatoria y barreras de entrada

Mesa redonda

Retos para la armonización regulatoria


Laboratorios Richmond SACIF

Company (SME)

Buenos Aires, Argentina